An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder - Jon E. Grant; Sophia Boutouis; Margaret O’Brien; Laurie Avila; Megha Neelapu; Dustin Ehsan (Clinical Neuropharmacology, 2026)